Brett Brodnax Acquires 35,000 Shares of Lumexa Imaging (NASDAQ:LMRI) Stock

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Director Brett Brodnax bought 35,000 shares of Lumexa Imaging stock in a transaction on Tuesday, May 19th. The stock was acquired at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the purchase, the director owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Lumexa Imaging Stock Performance

LMRI stock opened at $8.00 on Friday. The stock has a fifty day simple moving average of $9.63. Lumexa Imaging Holdings, Inc. has a twelve month low of $6.45 and a twelve month high of $19.45.

Institutional Investors Weigh In On Lumexa Imaging

Institutional investors have recently added to or reduced their stakes in the stock. Assetmark Inc. bought a new stake in Lumexa Imaging during the fourth quarter valued at about $36,000. Strs Ohio bought a new stake in Lumexa Imaging during the first quarter valued at about $38,000. PNC Financial Services Group Inc. bought a new stake in Lumexa Imaging during the first quarter valued at about $63,000. State of Wyoming bought a new stake in Lumexa Imaging during the first quarter valued at about $91,000. Finally, Barclays PLC bought a new stake in Lumexa Imaging during the fourth quarter valued at about $133,000.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LMRI shares. Weiss Ratings started coverage on Lumexa Imaging in a research note on Wednesday, May 13th. They issued a “sell (e-)” rating on the stock. Barclays cut their price target on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Raymond James Financial upgraded Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price target on the stock in a research note on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).